Visus Therapeutics cashes in €20m from LSP
Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
British drug developer Mission Therapeutics plc earns $20m milestone
British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Bayer takes over Vividion
The big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.
Spectricity raises €14m in Series B round
Belgian semiconductor specialist Spectricity BV has baged €14m to speed up the development of mobile hyperspectral sensors for medical applications.
BioFlo® 720: Experience Seamless Scalability of Your Bioprocess
Efficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
Abcam to acquire BioVision for $340m
Life sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Vaccine development – strategic approach
This white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
Byondis and Glycotope merge platforms to target carbohydrates
Cancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
Cancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.